enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. The Worst News for Celgene - AOL

   www.aol.com/news/2013-01-07-the-worst-news-for...

   Celgene presented today at J.P. Morgan's Annual Healthcare Conference. What was the worst news? The company projects 2013 sales for Revlimid of $4.1 billion to $4.2 billion, while expectations ...

3. Lenalidomide - Wikipedia

   en.wikipedia.org/wiki/Lenalidomide

   Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]

4. Celgene - Wikipedia

   en.wikipedia.org/wiki/Celgene

   In December 2005, Celgene received approval from the FDA to market Revlimid for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Focalin XR was later launched by Celgene and Novartis in 2005.

5. Celgene Corporation Announces Financial Outlook and ... - AOL

   www.aol.com/news/2013-01-07-celgene-corporation...

   Celgene Corporation Announces Financial Outlook and Preliminary 2012 Results 2012 Adjusted Diluted EPS Expected to be at the ... REVLIMID ® Achieved Q4 ... Cost of goods sold percentage of net ...

6. Sales of Celgene's multiple myeloma drug could triple ... - AOL

   www.aol.com/news/2009-12-01-sales-of-celgenes...

   There must be holiday cheer in the executive suite at biotech Celgene (CELG), where the stock is up 15% over last year. The Summit, N.J.-based company's cancer pill Revlimid generated $1.3 billion ...

7. 1 Big Growth Driver Withdrawn - AOL

   www.aol.com/2012/06/21/1-big-growth-driver-withdrawn

   Don't let the headlines fool you, Celgene's (NAS: CELG) application to market Revlimid, as a maintenance treatment for newl- diagnosed multiple myeloma patients, was rejected by the EU's Committee ...

8. Celgene's Revlimid-Rituximab Combo Gets Positive CHMP Opinion

   www.aol.com/news/celgenes-revlimid-rituximab...

   Celgene (CELG) gets a positive CHMP opinion, recommending the approval of Revlimid in combination with Rituxan for the treatment of adult patients with previously treated FL.

9. List of largest civil only pharmaceutical settlements - Wikipedia

   en.wikipedia.org/wiki/List_of_largest_civil_only...

   Thalomid/ Revlimid: Celgene Corporation [22] [23] $280,000,000 $280 million (civil only; non-intervened) Off-label promotion/ kickbacks/Medicare fraud False Claims Act/FDCA 2003 18 17 Zoladex: AstraZeneca [24] $355,000,000 $266 million ($355 million with criminal component) Medicare fraud Prescription Drug Marketing Act 2006 15 18 Temodar ...